bimagrumab tirzepatide plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Pharmacologic Disruption: How Emerging Weight

Since both medications are also authorized for treating diabetes and obesity, it would be valuable to explore the CoC for additional dual or triple endpoints that encapsulate both obesity and diabetes outcomes

Cardiovascular Conditions Some manufacturers believe there will be a minor impact on cardiovascular disease associated with obesity with GLP-1 drugs in the short and long term

How PlexusDx Supports a More Personalized Approach Genetic predispositions in GLP-1 receptor signaling, GIPR pathways, and metabolic genes (such as FTO and MC4R variants) may provide context for why some patients experience better appetite suppression or weight loss with specific GLP-1 formulations

, , ,